Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schramm, A; Schochter, F; Friedl, TWP; de Gregorio, N; Andergassen, U; Alunni-Fabbroni, M; Trapp, E; Jaeger, B; Heinrich, G; Camara, O; Decker, T; Ober, A; Mahner, S; Fehm, TN; Pantel, K; Fasching, PA; Schneeweiss, A; Janni, W; Rack, BK; SUCCESS Study Group.
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Clin Breast Cancer. 2017; 17(4):279-285
Doi: 10.1016/j.clbc.2016.11.008
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Trapp Elisabeth Katharina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Use of anthracycline-based chemotherapy in patients with early breast cancer (EBC) has been well-established but is often associated with cardiotoxicity. Based on data suggesting a limited benefit of anthracyclines in human epidermal growth factor receptor 2 (HER2)-negative patients, the Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies (SUCCESS) C study randomized patients to either anthracycline-containing or anthracycline-free chemotherapy. Given the proven prognostic value of circulating tumor cells (CTCs) in EBC, we compared the prevalence of CTCs after chemotherapy between both treatment arms for a preliminary efficacy assessment. The SUCCESS C trial (NCT00847444) is an open-label, phase III study randomizing 3547 patients with HER2-negative EBC to either 3 cycles of epirubicin, 5-fluorouracil, and cyclophosphamide followed by 3 cycles of docetaxel (FEC-DOC) or 6 cycles of docetaxel and cyclophosphamide (DOC-C). CTC status was prospectively evaluated in hormone receptor-positive patients at the time of last chemotherapy cycle using the US Food and Drug Administration-approved CellSearch System (Janssen Diagnostics). Data on CTC status were available for 1766 patients. Overall, CTCs were found in 221 (12.5%) patients. Univariate analyses revealed that presence of CTCs at time of last chemotherapy cycle was not significantly associated with tumor or patient characteristics (all P > .1). There was no significant difference with respect to presence of CTCs between patients randomized to FEC-DOC or DOC-C (11.5% vs. 13.6%; P = .18). The comparable prevalence of CTCs at the time of last chemotherapy cycle may indicate that anthracycline-free chemotherapy is equally effective to anthracycline-containing chemotherapy in HER2-negative, hormone receptor-positive EBC. However, efficacy data from the final survival analysis of SUCCESS C have to be awaited to confirm these preliminary findings. Copyright © 2017 Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Anthracyclines - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Biomarkers, Tumor - metabolism
- Breast Neoplasms - drug therapy
- Breast Neoplasms - metabolism
- Breast Neoplasms - pathology
- Carcinoma, Ductal, Breast - drug therapy
- Carcinoma, Ductal, Breast - metabolism
- Carcinoma, Ductal, Breast - pathology
- Carcinoma, Lobular - drug therapy
- Carcinoma, Lobular - metabolism
- Carcinoma, Lobular - pathology
- Chemotherapy, Adjuvant -
- Cyclophosphamide - administration & dosage
- Docetaxel -
- Epirubicin - administration & dosage
- Female -
- Fluorouracil - administration & dosage
- Follow-Up Studies -
- Humans -
- Middle Aged -
- Neoplasm Invasiveness -
- Neoplastic Cells, Circulating - pathology
- Prevalence -
- Prognosis -
- Receptor, ErbB-2 - metabolism
- Receptors, Estrogen - metabolism
- Receptors, Progesterone - metabolism
- Survival Rate -
- Taxoids - administration & dosage
- Young Adult -
- Find related publications in this database (Keywords)
- Adjuvant chemotherapy
- Anthracyclines
- Circulating tumor cells
- HER2-negative early breast cancer